rpmjResearch'n Practical Medicine JournalResearch and Practical Medicine Journal2410-1893"QUASAR", LLC10.17709/2409-2231-2015-2-2-63-72rpmj-64Research ArticleОбзорыReviewОктреотид в лечении нейроэндокринных опухолей: достигнут ли успех?Octreotide in the treatment of neuroendocrine carcinomas: Is the success achieved?МоргуновЛ. Ю.MorgunovL. Yu.morgunov.l.y@mail.ruГБОУ ВПО «МГМСУ имени А.И. Евдокимова» МЗ РФ 127473, Российская Федерация, Москва, ул. Делегатская, д.20, стр.1РоссияMoscow State University of Medicine and Dentistry named after A.I. Evdokimov Ulitsa Delegatskaya, 20/1, Moskva, 127473, RussiaRussian Federation201511062015226372Copyright © Моргунов Л.Ю., 20152015Моргунов Л.Ю.Morgunov L.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpmj.ru/rpmj/article/view/64

Диагностика и лечение функционирующих и нефункционирующих нейроэндокринных опухолей представляет собой сложную задачу. Единственным радикальным методом лечения этих новообразований остается хирургический, но опухоли нередко диагностируются уже на стадии метастазирования, когда возможна лишь паллиативная тактика. Октреотид у пациентов с нейроэндокринными опухолями остается препаратом с доказанной эффективностью, способным подавлять клиническую симптоматику карциноидного синдрома и обладающий антипролиферативной активностью, что позволяет улучшить качество жизни и увеличить выживаемость.

Diagnosis and treatment of functioning and non-functioning neuroendocrine tumors is a challenging task. Surgeru remains the only radical method of treatment of these tumors, but tumors often are diagnosed at the stage of metastasis, when only palliative treatment is possible. Octreotide in patients with neuroendocrine tumors remains a drug with proven efficacy that can suppress the clinical symptoms of carcinoid syndrome and has antiproliferative activity, which can improve the quality of life and prolong survival.

октреотиданалоги соматостатинанейроэндокринные опухоликарциноидный синдромoctreotidesomatostatin analoguesneuroendocrine carcinomascarinoid syndromeReferencesKaltsas G.A., Besser G.M., Grossman A.B. The Diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004; 25(3): 458-511.Kaltsas G.A., Besser G.M., Grossman A.B. The Diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004; 25(3): 458-511.Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A, Appetecchia M. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014; 5: 7.Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A, Appetecchia M. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014; 5: 7.Chuang CC, Bhurke S, Chen SY, Brulais S, Gabriel S. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study. J Med Econ. 2015; 18(2): 126-136.Chuang CC, Bhurke S, Chen SY, Brulais S, Gabriel S. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study. J Med Econ. 2015; 18(2): 126-136.Toth M. Drug therapy for neuroendocrine tumours. Orv Hetil. 2013;154 (39): 1556-1564.Toth M. Drug therapy for neuroendocrine tumours. Orv Hetil. 2013;154 (39): 1556-1564.Pavel M, Kidd M, Modlin I. Systemic therapeutic options for carcinoid. Semin Oncol. 2013; 40 (1): 84-99.Pavel M, Kidd M, Modlin I. Systemic therapeutic options for carcinoid. Semin Oncol. 2013; 40 (1): 84-99.Demirkan BH, Eriksson B. Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J Gastroenterol. 2012; 23(5): 427-437.Demirkan BH, Eriksson B. Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J Gastroenterol. 2012; 23(5): 427-437.Bergsland EK. The evolving landscape of neuroendocrine tumors. Semin Oncol. 2013; 40(1): 4-22.Bergsland EK. The evolving landscape of neuroendocrine tumors. Semin Oncol. 2013; 40(1): 4-22.Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res. 2012; 5(5): 161-168.Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res. 2012; 5(5): 161-168.Young K, Iyer R, Morganstein D, Chau I, Cunningham D, Starling N. Pancreatic neuroendocrine tumors: a review. Future Oncol. 2015; 11(5): 853-864.Young K, Iyer R, Morganstein D, Chau I, Cunningham D, Starling N. Pancreatic neuroendocrine tumors: a review. Future Oncol. 2015; 11(5): 853-864.Jia W.D., Xu G.L., Sun H.C., et al. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo // Hepatobiliary Pancreat Dis Int. 2003; 2(3): 404-409.Jia W.D., Xu G.L., Sun H.C., et al. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo // Hepatobiliary Pancreat Dis Int. 2003; 2(3): 404-409.Li SC, Martijn C, Cui T, Essaghir A, Luque RM, Demoulin JB, Castano JP, Oberg K, Giandomenico V. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. PLoS One. 2012; 7(10): e48411.Li SC, Martijn C, Cui T, Essaghir A, Luque RM, Demoulin JB, Castano JP, Oberg K, Giandomenico V. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. PLoS One. 2012; 7(10): e48411.Sideris L, Dube P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012; 17(6): 747-755.Sideris L, Dube P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012; 17(6): 747-755.Al-Efraij K, Aljama MA, Kennecke HF. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med. 2015. doi: 10.1002/cam4.435.Al-Efraij K, Aljama MA, Kennecke HF. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med. 2015. doi: 10.1002/cam4.435.Adam N, Lim SS, Ananda V, Chan SP. VIPoma syndrome: challenges in management. Singapore Med J. 2010; 51(7): e129-132.Adam N, Lim SS, Ananda V, Chan SP. VIPoma syndrome: challenges in management. Singapore Med J. 2010; 51(7): e129-132.Нейроэндокринные опухоли: руководство для врачей. Под ред. М. Кэплина, Л. Квопса. М., Практическая медицина, 2010. 224 с.Нейроэндокринные опухоли: руководство для врачей. Под ред. М. Кэплина, Л. Квопса. М., Практическая медицина, 2010. 224 с.Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumours. Cancer. 2003; 97: 934–959.Modlin I.M., Lye K.D., Kidd M. A 5-decade analysis of 13,715 carcinoid tumours. Cancer. 2003; 97: 934–959.Нейроэндокринные опухоли желудочно–кишечного тракта. Принципы диагностики и лечения / Под ред. В.А. Горбунова, А.В. Егорова, А.В. Кочатков. – М., 2009. – 196 с.Нейроэндокринные опухоли желудочно–кишечного тракта. Принципы диагностики и лечения / Под ред. В.А. Горбунова, А.В. Егорова, А.В. Кочатков. – М., 2009. – 196 с.Igaz P. Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials. Orv Hetil. 2014; 155(48): 1908-1912.Igaz P. Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials. Orv Hetil. 2014; 155(48): 1908-1912.Oberg K. Pancreatic endocrine tumors. Semin. Oncol. 2010; 37: 594–618Oberg K. Pancreatic endocrine tumors. Semin. Oncol. 2010; 37: 594–618Kaltsas G., Androulakis I.I., de Herder W.W. et al. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr. Relat. Cancer. 2010; 17: 173–193.Kaltsas G., Androulakis I.I., de Herder W.W. et al. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr. Relat. Cancer. 2010; 17: 173–193.Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014; 19(9): 930-936.Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014; 19(9): 930-936.Jann H, Denecke T, Koch M, Pape UF, Wiedenmann B, Pavel M. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology. 2013; 98(2):137-143.Jann H, Denecke T, Koch M, Pape UF, Wiedenmann B, Pavel M. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin. Neuroendocrinology. 2013; 98(2):137-143.Miura M, Shibahara H, Morita K, Matsui K, Itoh Y, Shimizu J, Takeuchi A, Narita M, Nishimura D, Katada N. Subcutaneous continuous injection of octreotide decreased the tumor marker levels and induced cystic necrosis of the tumors in a case of pancreatic neuroendocrine tumor with multiple hepatic metastases. Nihon Shokakibyo Gakkai Zasshi. 2015; 112(3): 537-546.Miura M, Shibahara H, Morita K, Matsui K, Itoh Y, Shimizu J, Takeuchi A, Narita M, Nishimura D, Katada N. Subcutaneous continuous injection of octreotide decreased the tumor marker levels and induced cystic necrosis of the tumors in a case of pancreatic neuroendocrine tumor with multiple hepatic metastases. Nihon Shokakibyo Gakkai Zasshi. 2015; 112(3): 537-546.Goto W, Shimizu S, Kotsuka M, Sakae M, Kanazawa A, Tsukamoto T, Yamashita Y, Nishiguchi Y Two cases of neuroendocrine tumors of the pancreas with multiple liver metastases treated by use of degradable starch microspheres and octreotide. Gan To Kagaku Ryoho. 2014; 41(12): 2139-2141Goto W, Shimizu S, Kotsuka M, Sakae M, Kanazawa A, Tsukamoto T, Yamashita Y, Nishiguchi Y Two cases of neuroendocrine tumors of the pancreas with multiple liver metastases treated by use of degradable starch microspheres and octreotide. Gan To Kagaku Ryoho. 2014; 41(12): 2139-2141Shen C, Shih YC, Xu Y, Yao JC. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014; 120(13): 2039-2049.Shen C, Shih YC, Xu Y, Yao JC. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014; 120(13): 2039-2049.Uhlyarik A, Lahm E, Vachaja J, Papai Z. Treatment of metastatic midgut neuroendocrine tumour associated with carcinoid syndrome. Orv Hetil. 2014; 155(5): 194-198.Uhlyarik A, Lahm E, Vachaja J, Papai Z. Treatment of metastatic midgut neuroendocrine tumour associated with carcinoid syndrome. Orv Hetil. 2014; 155(5): 194-198.Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, De Luca L, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, de Luca di Roseto C, Colao A, Faggiano A; Multidisciplinary Group for Neuroendocrine Tumors of Naples. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf). 2014; 80(6): 850-855.Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, De Luca L, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, de Luca di Roseto C, Colao A, Faggiano A; Multidisciplinary Group for Neuroendocrine Tumors of Naples. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf). 2014; 80(6): 850-855.Yoshida Y, Sugawara N, Minami T, Iwata N, Ikeda K, Endoh T, Sasano H. A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide. Nihon Shokakibyo Gakkai Zasshi. 2013; 110(4): 660-668.Yoshida Y, Sugawara N, Minami T, Iwata N, Ikeda K, Endoh T, Sasano H. A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide. Nihon Shokakibyo Gakkai Zasshi. 2013; 110(4): 660-668.Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013; 40(1):56-68. doi: 10.1053/j.seminoncol.2012.11.006Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013; 40(1):56-68. doi: 10.1053/j.seminoncol.2012.11.006Igarashi H, Hijioka M, Lee L, Ito T. Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs. J Hepatobiliary Pancreat Sci. 2015. doi: 10.1002/jhbp.227.Igarashi H, Hijioka M, Lee L, Ito T. Biotherapy of pancreatic neuroendocrine tumors using somatostatin analogs. J Hepatobiliary Pancreat Sci. 2015. doi: 10.1002/jhbp.227.Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T; RADIANT-2 Study Group. Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study. Oncologist. 2013; 18(1): 46-53.Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T; RADIANT-2 Study Group. Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT-2 Study. Oncologist. 2013; 18(1): 46-53.Емельянова Г.С., Маркович А.А, Кузьминов А.Е., Орел Н.Ф. , Горбунова В.А. «Применение отечественного аналога пролонгированного соматостатина Октреотид-депо™ в дозах 20–40 мг у больных НЭО. Опыт отделения химиотерапии РОНЦ» Онкология, гематология и радиология, 2012, N 4, стр. 3-6.Емельянова Г.С., Маркович А.А, Кузьминов А.Е., Орел Н.Ф. , Горбунова В.А. «Применение отечественного аналога пролонгированного соматостатина Октреотид-депо™ в дозах 20–40 мг у больных НЭО. Опыт отделения химиотерапии РОНЦ» Онкология, гематология и радиология, 2012, N 4, стр. 3-6.Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada F. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer. 2014; 120(16): 2457-2463.Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada F. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer. 2014; 120(16): 2457-2463.Lynggard LA, Nielsen EH, Laurberg P. Carcinoid syndrome caused by a serotonin-secreting pituitary tumour. Eur J Endocrinol. 2014; 170(2): K5-9.Lynggard LA, Nielsen EH, Laurberg P. Carcinoid syndrome caused by a serotonin-secreting pituitary tumour. Eur J Endocrinol. 2014; 170(2): K5-9.Rodrigues P, Castedo JL, Damasceno M, Carvalho D. Ectopic Cushing's syndrome caused by a pulmonary ACTH-secreting tumor in a patient treated with octreotide. Arq Bras Endocrinol Metabol. 2012; 56(7): 461-464.Rodrigues P, Castedo JL, Damasceno M, Carvalho D. Ectopic Cushing's syndrome caused by a pulmonary ACTH-secreting tumor in a patient treated with octreotide. Arq Bras Endocrinol Metabol. 2012; 56(7): 461-464.Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013; 42(4): 557-577.Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013; 42(4): 557-577.

The authors declare that there are no conflicts of interest present.